OCL
Objective Corporation Limited
🇦🇺 ASX
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
+ 43.68%
Annual Growth
5 years average annual growth
💰
1.27%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
19
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Objective Corp. Ltd. engages in the supply of information technology software and services. The company is headquartered in North Sydney, New South Wales and currently employs 5,000 full-time employees. The company went IPO on 2000-08-17. The firm's product categories include content solutions, planning & building, and regulatory solutions. Its content solutions include content and process management (Objective Nexus), federated information governance (Objective 3Sixty), secure external file collaboration (Objective Connect), and automated redaction (Objective Redact). The firm's planning & building product includes planning and development platform (Objective Build), building plan assessment tools (Objective Trapeze) and planning policy management (Objective Keyplan). Its regulatory solutions include data-driven regulation (Objective RegWorks) and regulated document production (Objective Keystone). The firm's solutions include local government; federal and state government; regulation; information governance, and wealth, banking and insurance. The company provides consulting and managed services.
📈 Performance
Price History
+1173.53%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
1.27%
💰 Annual Dividend Earnings Per $1,000 invested**
$12.72
💰 Most Recent Dividend Franked Percentage Estimate
0.00%
💰 Average Dividend Franked Percentage Estimate
98.15 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of OCL, your last dividend payment(s) would have been:
$ 66.72
on Tue Sep 17 2024
$ 85.1
on Mon Sep 16 2024
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2024
$0.17
0.00%
2023
$0.14
Infinity%
2022
$0.11
0.00%
2021
$0.09
Infinity%
2020
$0.07
Infinity%
2019
$0.05
Infinity%
2018
$0.05
Infinity%
2017
$0.04
Infinity%
2016
$0.04
Infinity%
2015
$0.04
100.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
16
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
7
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$17.32
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in OCL
19
📊 Total Capital Earnings
$22K
🔃 Average investment frequency
20 weeks
💵 Average investment amount
$1,718
⏰ Last time a customer invested in OCL
4 days
OCL investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
23%
50k - 100k
58%
Less than 50k
19%
👶 Age of investors
18 - 25
26 - 34
16%
35 - 90
74%
🙋 Legal gender of investors
Female
32%
Male
68%
Pearlers who invest in OCL also invest in...
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
19.63%
📊 Share price
$61.01 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
RMD
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,140 full-time employees. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.
🙌 Performance (5Yr p.a)
14.74%
📊 Share price
$37.28 AUD
🩺 HEALTH CARE
🌳 ENVIRONMENTAL
🕊️ SOCIALLY AWARE
📈 HIGH PRICE GROWTH
Audinate Group Ltd. engages in the development and commercialization of audio visual software and hardware. Its principal activity is the development and sale of digital AV networking solutions. Its products include Dante AVIO adapters, software, Dante-enabled products, solutions for manufacturers and solutions for software developers. Dante is a technology platform that distributes digital audio and video signals over computer networks. Dante comprises software and chips, cards and modules that are sold to and integrated inside the AV products of its original equipment manufacturer (OEM) customers. The company also provides a series of products and services for AV professionals, including AVIO adapters and management and control software. Dante replaces all of those connections with a computer network, sending video or hundreds of channels of audio over slender ethernet cables with digital fidelity. Dante is available in over 3,500 products from more than 500 manufacturers.
🙌 Performance (5Yr p.a)
0.17%
📊 Share price
$8.47 AUD
🔨 COMMERCIAL SERVICES & SUPPLIES
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
4.35%
📊 Share price
$104.33 AUD
⛳️ DIVERSIFIED
🧱 MATERIALS
💸 FINANCIALS
CSL
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
🙌 Performance (5Yr p.a)
0.22%
📊 Share price
$276.47 AUD
🕊️ SOCIALLY AWARE
🧬 BIOTECHNOLOGY
Want more shares? Try these...
Oceana Lithium Ltd. is a mineral exploration and development company, which engages on the discovery and delineation of lithium mineral resources. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-07-01. The firm is focused on the discovery and delineation of lithium mineral resources in two mining-friendly jurisdictions, the state of Ceara, Brazil, and the Northern Territory, Australia. The firm's projects include Solonopole Lithium Project and the Napperby Lithium project. The Solonopole lithium project, located in Ceara State, northeastern Brazil, consists of approximately eight mining permits covering approximately 114 square kilometers (Km2). The Napperby lithium project consists of a granted exploration license (EL32836) covering an area of approximately 650km2 and an exploration license application (ELA32841) covering an area of more than 512km2. The Napperby lithium project is located within the Northern Arunta pegmatite province near the settlement of Ti Tree, approximately 250km northwest of Alice Springs and 250km south of Tennant Creek.
📊 Share price
$0.03 AUD
⛏️ MINING
Octava Minerals Ltd. operates as a mineral exploration and development company. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2022-09-16. The firm is engaged in acquiring interests in a portfolio of mineral exploration properties within Western Australia with the main focus being on lithium, gold, platinum group metals (PGMs), and nickel sulphide prospects. Its projects include East Pilbara (Talga), East Kimberley (Panton North and Copernicus North), and Yallalong. The East Pilbara (Talga) project comprises eight granted exploration licenses prospective for lithium and gold, located approximately 30 kilometers (km) to the north of the Marble Bar town site. The East Kimberley project comprises two tenements, the Panton North project (E80/5455) and the Copernicus North project (E80/5459) located in the Halls Creek Orogen. The Company’s Yallalong project is located in the northwestern portion of the Murchison region approximately 220km to the northeast of the port of Geraldton and covers an area of about 65.5km2.
📊 Share price
$0.12 AUD
⛏️ MINING
Oceania Healthcare Ltd. engages in the provision of health care solution. The firm operates through three segments: care operations, village operations and others. The care segment is engaged in providing products, such as traditional care beds and care suites. The segment is involved in the provision of accommodation, care, and related services to the Company’s aged care residents; and services, such as meals and care packages to independent living residents. The village operations segment is engaged in providing products, such as independent living and rental properties. The segment is involved in the provision of accommodation and related services to independent residents in the Company’s retirement villages. The other segment is involved in the provision of support services to the Company, which includes administration, marketing, and operations. In addition, this segment includes the provision of training by the Wesley Institute of Nursing Education.
🙌 Performance (5Yr p.a)
-6.41%
📊 Share price
$0.70 AUD
🩺 HEALTH CARE
Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The firm is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
🙌 Performance (5Yr p.a)
1.96%
📊 Share price
$0.61 AUD
🧬 BIOTECHNOLOGY
🕊️
Social Score
71
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.